Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has ...
CEO Andrew Obenshain said the company is preparing for a second-half phase 3 readout for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH), describing the trial as fully enrolled ...
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra Poster of ...
The MarketWatch News Department was not involved in the creation of this content. Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and ...
Please provide your email address to receive an email when new articles are posted on . Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, ...
MASH prevalence is projected to remain under 5% by 2040, with new treatments like resmetirom now available. Diagnostic challenges and underestimation in claims data affect accurate prevalence ...
Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles "The encouraging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results